一分钟看懂
这是一项关于尿路上皮癌的II 期 / III 期研究，登记的药物或干预包括Biospecimen Collection；cfDNA or ctDNA Measurement；Computed Tomography；Cystoscopy；Magnetic Resonance Imaging；Nivolumab；Questionnaire Administ，当前状态为招募中。登记地点显示中国Phoenix、Tucson、Fayetteville、Rogers等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Biospecimen Collection；cfDNA or ctDNA Measurement；Computed Tomography；Cystoscopy；Magnetic Resonance Imaging；Nivolumab；Questionnaire Administration；Relatlimab · II 期 / III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Cancer Center at Saint Joseph's · Phoenix
- Mayo Clinic Hospital in Arizona · Phoenix
- University of Arizona Cancer Center-Orange Grove Campus · Tucson
- Banner University Medical Center - Tucson · Tucson
- University of Arizona Cancer Center-North Campus · Tucson
- Highlands Oncology Group - Fayetteville · Fayetteville
- Highlands Oncology Group - Rogers · Rogers
- Highlands Oncology Group · Springdale
- Kaiser Permanente-Anaheim · Anaheim
- Kaiser Permanente-Baldwin Park · Baldwin Park
- Kaiser Permanente-Bellflower · Bellflower
- Kaiser Permanente Dublin · Dublin
- Kaiser Permanente-Fontana · Fontana
- Kaiser Permanente-Fremont · Fremont
- Kaiser Permanente Fresno Orchard Plaza · Fresno
- Kaiser Permanente-Fresno · Fresno
- Kaiser Permanente South Bay · Harbor City
- Kaiser Permanente-Irvine · Irvine
- UC San Diego Moores Cancer Center · La Jolla
- Keck Medicine of USC Koreatown · Los Angeles
- Kaiser Permanente Los Angeles Medical Center · Los Angeles
- Los Angeles General Medical Center · Los Angeles
- USC / Norris Comprehensive Cancer Center · Los Angeles
- Kaiser Permanente West Los Angeles · Los Angeles
- UCLA / Jonsson Comprehensive Cancer Center · Los Angeles
- Kaiser Permanente- Modesto MOB II · Modesto
- Kaiser Permanente-Modesto · Modesto
- USC Norris Oncology/Hematology-Newport Beach · Newport Beach
- Kaiser Permanente-Oakland · Oakland
- Kaiser Permanente-Ontario · Ontario
公开的入选条件
- * PRE-REGISTRATION (STEP 0): Histologically confirmed muscle-invasive urothelial carcinoma of the urethra, bladder, ureter or renal pelvis
- * PRE-REGISTRATION (STEP 0): Variant histology, including neuroendocrine differentiation, sarcomatoid, micropapillary, glandular, trophoblastic, Mullerian, is allowed if urothelial cancer is predominant histology (any amount of squamous differentiation is allo
- * PRE-REGISTRATION (STEP 0): Radical surgery (cystectomy with lymph node dissection or nephroureterectomy or ureterectomy) must be ≥ 3 weeks and ≤ 12 weeks (central Signatera pathway) or ≤ 16 weeks (commercial Signatera pathwary) prior to pre-registration. Pat
- * PRE-REGISTRATION (STEP 0): Patients who have had a partial cystectomy as definitive therapy are not eligible
- * PRE-REGISTRATION (STEP 0): No gross cancer at the surgical margins. Microscopic invasive urothelial carcinoma at the surgical margins (i.e., "positive margins") are allowed. Carcinoma in situ (CIS) at margins is considered negative margins
- * PRE-REGISTRATION (STEP 0): No evidence of residual cancer or metastasis after radical cystectomy or nephroureterectomy or ureterectomy (imaging is not required prior to pre-registration but is required prior to registration)
- * PRE-REGISTRATION (STEP 0): Have undergone a radical cystectomy nephroureterectomy, or ureterectomy with pathological evidence of urothelial carcinoma at high risk of recurrence as described in one of the two scenarios below (i or ii). The 7th edition of Amer
- (i) Patients who have not received neoadjuvant systemic therapy: pT4N0 or pTanyN+ on radical surgery pathology specimen (i.e., cystectomy, nephroureterectomy, or ureterectomy) and are not eligible for adjuvant cisplatin chemotherapy
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT05987241；登记信息更新于 2026-09-17。